neutrophils and lymphocytes, 242 tools, 248
|
|
- Charlotte Osborne
- 5 years ago
- Views:
Transcription
1 Index A Acute eosinophilic pneumonia (AEP), Acute interstitial pneumonia (AIP) diffuse alveolar damage (DAD), 91 Hamman-rich disease, 91 Acute lung injury (ALI), 51 AEP. See Acute eosinophilic pneumonia AIP. See Acute interstitial pneumonia ALI. See Acute lung injury Allergic alveolitis. See Hypersensitivity pneumonitis Alveolar hemorrhage, Alveolar hemorrhage syndromes biopsy diagnosis, 63 caveats, differential diagnosis, 63 histologic findings, Alveolitis foamy alveolar macrophages, 45 plasma cell, 43 sarcoidosis, 42 subclinical, 45 Amyloidosis (AL) AA, 307 characteristics, 307 diffuse alveolar septal, nodular parenchymal, 308 plasma cell, 307 primary and secondary, tracheobronchial, 308 Angiotensin converting enzyme (ACE), Anti glomerular basement membrane (Anti-GBM) disease, 265 Antimalarial agents, Antineutrophic cytoplasmic autoantibodies (ANCA) anti-gbm, 366 C-ANCA and P-ANCA, 366 Churg Strauss syndrome, 366, 379 classic polyarteritis nodosa, 378 clinical features, 367 connective tissue disorders, 366 Goodpasture s syndrome, 366, 382 granular cytoplasmic staining, 366 immunosuppressive therapy, 366 microscopic polyangiitis, 377 pulmonary vasculitides, 366 Wegener s granulomatosis, 366, 369, 370, 375, 376 Anti-TNF agents demyelinating diseases, 112 hepatitis B, 113 infliximab, 111 local and systemic reactions, 113 monitoring guidelines, M. tuberculosis, pneumonia, 113 pregnancy, 113 randomized pulmonary disease trials, 112 rheumatoid arthritis, 111 Anti-TNF drugs, 229 Aspiration bronchiolar disease, 306 fibrosing lung disease, gastroesophageal, 305 ATP-binding cassette transporter A3 (ABCA3), 297 Azathioprine connective tissue disease, 229 drug therapy, B BAC. See Bronchioloalveolar carcinoma BAL. See Bronchoalveolar lavage BAL fluid (BALF) AM dominant cell type, 42 foamy/lipidladen, 42 phagocytized hemosiderin, 42 cell counting, 40 diagnostic applications, 38 disease-specific features, eosinophils, 44 immunohistiochemistry, lymphocytes CD4:CD8 ratio, 42 cellular profile, EAA patients, 42 Crohn s disease and cirrhosis, 42 mature lym, 42 sarcoidosis and EAA, mast cells, 44 R.P. Baughman and R.M. du Bois (eds.), Diffuse Lung Disease: A Practical Approach, DOI / , Springer Science+Business Media, LLC
2 388 Index BAL fluid (BALF) (cont.) plasma cells, 43 PMN, 43 reactive type II pneumocytes, 44 Behçet s disease characterization, 380 diagnosis, 380 embolization therapy, 381 massive hemoptysis, 380 prognosis, 381 symptomatology, 380 use azothioprine and cyclophosphamide, 381 Biological controls cotes states, 81 staff members, 79 trend analyses, 81 Bladder cancer, 109 Bronchiolitis acute inhalation injury, 349 biopsy diagnosis, 68 and bronchiectasis consequences and infections, 357 CT scan, 357 cylindrical, varicose and cystic types, 357 cystic fibrosis, 358 definition, 357 development, 358 indentify, 357 lesions, 357 mosaic attenuation, 357 Swyer-James and Kartagener syndrome, 358 caveats, 68 chronic cellular, classification acute/chronic, 346 alveoli, 346 bronchiectasis development, 346 clinical implications, 346 constrictive obliterans, etiological, 344, 345 inflammatory process, 346 obliterans features, pathologics, 344 proliferative obliterans, 346 connective tissue diseases ( see Connective tissue diseases) COPD, 356 cryptogenic constrictive explanation, 355 improvement, 355 lung biopsy, 355 symptom, 355 transmural, 355 X-ray, 355 defined, 344 differential diagnosis, 68 diffuse inflammatory lung disease, 358 diffuse panbronchiolitis, drug-induced bronchiolitis features, 349 iatrogenic, organizing pneumonia, 349 isolation, 349 sauropus androgynus, 349 follicular alveolar septal inflltration, 357 definition, infections and imaging, 357 therapy, 357 food flavorer s lung, 350 image patterns centrilobular nodules, 347 CT and HRCT, 347 differences, 347 mosaic attenuation, 347 tree-in-bud, 347 infection acute, 348 Aspergillus, 348 Bronchoalveolar lavage (BAL), 348 nontuberculous mycobacteria, 348 postinfectious, 348 viruses and bacteria consequences, 348 inflammatory and fibrotic changes, 66 interstitial lung disease, 356 langerhans cell histiocytosis, 359 latency, 350 lung function test airflow obstruction, 346 BOS and lung transplantation, 347 mild airways obstruction syndrome, lung transplantation ( see Lung transplantation) lymphangioleiomyomatosis, 359 malignant, 358 mesenchymal reaction, 66 mineral dust develop airflow obstruction, 349 smoking, 349 morphological lesions, 344 neuroendocrine cell hyperplasia, obliteration, plastic manufacture, 350 respiratory disease, 356 size and communications, 344 smoking, stabilize lung function, 350 therapy anti-inflammatory, immunosuppressive, 347 macrolide, 348 nasal cannula, 348 Bronchioloalveolar carcinoma (BAC), 22, 23, 311 Bronchoalveolar lavage (BAL) bronchoscopy, CD4/CD8 ratio, 247 confounding factors, 40 cytology, 272 description, 38 DILD, 38 etiological factor, 38 immunoglobulins, 248 lymphocytes, 243, 244, 247
3 Index neutrophils and lymphocytes, 242 tools, 248 C Chest radiograph (CXR), sarcoidosis description, 140 organ involvement, patients, 157 parenchymal disease, 154 radiographic resolution, 166 scadding scale, 142, 143 surface echocardiogram, 145 Childhood interstitial lung diseases (ILDs) ABCA3 gene mutations, 282, 283 adult disorders, 279, 281 aspiration, bronchiolitis obliterans adenovirus infection, 288 diagnosis, 288 therapies, classification and terminology, connective tissue disease, 289 description, diagnosis approach, 275 bronchoscopy and BAL, genetic test, history and physical examination, HRCT, 277 initial clinical testing, 276 lung biopsy, 278 PFT, 277 epidemiology, 274 follicular bronchiolitis/lymphocytic pneumonitis, 289 hypersensitivity pneumonitis, 287 lung biopsy, 279 lymphocytic inflammation, management, 278 mutation, 272 NEHI, neuroendocrine cell hyperplasia, 272, 273 PAP, pathogenesis, PIG, pulmonary hemorrhage syndromes, 287 SFTPB, 279, 281, 282 SFTPC, Children, ILDs. See Childhood interstitial lung diseases Churg Strauss syndrome clinical presentation and diagnosis allergic/asthmatic phase, 378 alveolar-type inflltrates, 378 ANCA presentation, 379 corticosteroid dose, 379 description, 378 development, 379 eosinophilic phase, 378 histopathology, 378 life-threatening, 378 necrotizing granuloma, renal failure, 378 skin biopsy, 379 steroid taper, 379 use leukotriene receptor, 379 parenchymal necrosis region, 60, 62 prognosis and treatment corticosteroids, 379 deaths, cardiac involvement, 379 documented outcomes, 379 hydroxyurea, alpha-interferon and rituximab, 379 Collagen vascular diseases (CVDs) biopsy diagnosis, 57 caveats, differential diagnosis, histologic findings, 56 Combined pulmonary fibrosis and emphysema, 264 Computed tomography (CT) high-resolution, 277 lung disease, 320 small airways diseases, 30 Connective tissue diseases (CTD) bronchiolitis, 232 follocular bronchiolitis, 351 histopathological considerations, ILD anti-tnf drugs, 229 assessment and management, 230 autoantibodies, azathioprine, 229 bronchoscopic evaluation, 221 clinical manifestation, 223 corticosteroids, cyclophosphamide, 228 cyclosporine, 229 drug induced lung disease, 220 lung transplantation, 230 management considerations, 227 mycophenolate mofetil, pulmonary hypertension, surgical lung biopsy, tacrolimus, 229 lung-dominant, lupus erythematosus, 351 multidisciplinary approach, NSIP, 196, 225 pulmonary manifestations, 218 radiologic characteristics, 197, rheumatoid arthritis characteristics, 350 defined, 350 development, 351 diagnosis, 350 histopathologic lesions, 351 HRCT and CT, 350 increase airflow obstruction, 351 interstitial lung disease, 350 lung function test, 350 obliterative bronchiolitis, 351 penicillamine, 351 treatment, 350
4 390 Index Connective tissue diseases (CTD) (cont.) rheumatologic diseases, 218, 219 screening, Sjögren syndrome, 351 UCTD, 197, 201, 225 COP. See Cryptogenic organizing pneumonia Corticosteroids connective tissue disease, drug therapy, 102, Cryptogenic organizing pneumonia (COP) community-acquired pneumonia, 90 HRCT scanning, 91 organizing pneumonia, 90, 91 CTD. See Connective tissue disease CVDs. See Collagen vascular diseases CXR. See Chest radiograph (CXR), sarcoidosis Cyclophosphamide connective tissue disease, 228 drug therapy, Cyclosporine, 229 Cytoplasmic-Antineutrophic cytoplasmic autoantibodies (C-ANCA), 366, 369, 370, 377, 378, 382 D DAD. See Diffuse alveolar damage Dendritic cells (DC), 196 Desquamative interstitial pneumonia (DIP). See also Respiratory bronchiolitis-associated interstitial lung disease alveolar macrophage accumulation, 92 chest imaging, 259 clinical features, 259 clubbing, 91 diagnosis, 260 history, 258 lower lobe ground glass abnormality, 92 pathology, physiology, 259 relationship, smoking, 259 treatment, 260 Diagnosis NSIP agreement, 200 histological features, 201, 209 HRCT, 200 radiologic (see Radiologic evaluation) Differential diagnosis DILD, 42 inflammatory cells, 42 Diffuse alveolar damage (DAD), 51 Diffuse lung disease (DLD) alveolar hemorrhage syndromes biopsy diagnosis, 63 caveats, differential diagnosis, 63 histologic findings, bronchiolitis, classification connective tissue disease, 87 drug-induced-related, 87 environmental exposure, 87 IIP, primary disease, collagen vascular diseases, cytotoxic therapy, 98 diagnosis, 50 diagnostic approach algorithm, 92, 93 bronchoscopy, 94 histopathology, 95 pulmonary function testing, 94 radiology, 94 drug reaction caveats, clinical patterns, 69 fludarabine, histologic findings acute lung injury (ALI), 51 alveolar space inflammation, 51 DAD, 51 fibrosis, 51 hypersensitivity pneumonitis (HP), 52 interstitial infiltrate, 51 type 2 cell proliferation, 51 HRCT, 50, 96, 97 hypersensitivity pneumonitis caveats, 65 differential diagnosis, histologic findings, 64 idiopathic pulmonary fibrosis, lymphangioleiomyomatosis biopsy diagnosis, 66 caveats, 66 differential diagnosis, histologic findings, 65 nonspecific interstitial pneumonia biopsy diagnosis, 56 caveats, 56 differential diagnosis, histologic findings, 55 pathology reports, 53 pneumoconioses, pulmonary alveolar proteinosis, 65 randomized, placebo-controlled trials, 95, 96 sarcoidosis, surgical lung biopsy, role, systematic approach, 86 tissue sampling cytologic and histologic techniques, 50 inflammation and fibrosis, 51 TBBx, 50 vasculitis, DIP. See Desquamative interstitial pneumonia Disease-specific features AIP, 46 chronic interstitial lung disease, 47 diffuse interstitial lung disease, 46 focal lung sensitization, 45 fungal infections, 45 DLD. See Diffuse lung disease
5 Index DLD, radiologic signs consolidation description, 18, 20 differential diagnosis, 18, 19 crazy paving pattern description, 21, 22 occurrences, cysts centrilobular emphysema, 22, 23 pulmonary, 22, 23 ground-glass attenuation description, 18, 20 differential diagnosis, 18, 19 honeycombing, 22 lines crazy paving pattern, reticular, 21 thickened interlobular septa, mosaic attenuation, 23, 24 pattern, nodules centrilobular, 18, 20 description, 18 differential diagnosis, 18, 20 perilymphatic, 18, 20 soft tissue density, 18, 20 tree-in-bud pattern, 18, 21 traction bronchiectasis/bronchiolectasis, 22 Drug-induced diffuse lung disease (DI-DLD) ARDS and ILD, 326 bronchoscopy, lung biopsy, and BAL, 333 clinical patterns, description, 326 disorders and therapy, 326 estimation, 331 histological data, 333 history and physical examination, HRCT, 331 limited dose, 331 mechanism, injury, 332 nitrofurantoin, 334 oncological patients, diagnosis, 331 polymyxin and aminoglycoside antibiotics, 334 pulmonary function tests, 334 pulmonary toxic effects, 331 risk and adverse reactions, sulfasalazine, 334 Drug-induced lung disease, 86, 87 Drug therapy antimalarial agents, anti-tnf agents demyelinating diseases, 112 hepatitis B, 113 infliximab, 111 local and systemic reactions, 113 monitoring guidelines, M. tuberculosis, pneumonia, 113 pregnancy, 113 randomized pulmonary disease trials, 112 rheumatoid arthritis, 111 azathioprine, classification, common toxicities and suggested monitoring, 103 corticosteroids, 102, cyclophosphamide, leflunomide, 106 methotrexate, mycophenolate mofetil, 108 N -acetyl cysteine, 107 pirfenidone, rituximab, sirolimus, 114 thalidomide, 110 usual dosage, 103 Dyspnea, 4, , 275, 302 E EAA. See Extrinsic allergic alveolitis Endobronchial ultrasound, 155 Environmental exposure, 87 Eosinophilia, Eosinophilic granuloma Histiocytosis X, lung biopsies, smoking, 260 unifocal LCH, 261 Epidemiology fibrotic obliteration, 124 IPF, 124 LAM, 124 pathophysiology concomitant emphysema, 127 CREST syndrome, 125 development and severity, PH, 125 genetic predisposition, 127 hilar lymph nodes, 125, 126 PH classification, WHO, 125 role, pulmonary endothelial dysfunction, 126 PFT and FVC, 124 PLCH, 124 prevalence, PH and sarcoidosis, 124 scleroderma, 124 SSc-PAH, 124 Erdheim Chester disease, 309 Extrapulmonary sarcoidosis acute sarcoid arthritis, 151 antimalarials and methotrexate, 162 azathioprine, corticosteroids, dysregulation, calcium metabolism, 149 eye corticosteroids, 146 CXR and CT, lacrimal gland and optic neuritis, 145 lacrimal gland biopsies, 146 uveitis, isocular, 145 heart diagnosis, granulomatous inflammation, 148 medications,
6 392 Index Extrapulmonary sarcoidosis (cont.) myriad, cardiac disorders, 148 noninvasive tests, 149 prognosis, heart failure, 149 leflunomide and cyclophosphamide, 163 liver granulomatous hepatitis, 147 hepatomegaly and cirrhosis, 147 symptoms, 147 lupus pernio skin lesions, nose, lymphadenopathy and skeletal muscle weakness, 151 manifestations and treatment, 152 morbidity and impact, patients life, 145 mycophenolate and mycophenolic acid, 163 neurologic cerebral and spinal, 148 cranial nerves, neurosarcoidosis, 147 treatment, corticosteroids, 148 palpable breast mass/lesion, mammography, 151 reproductive tracts, 151 sarcoid bone involvement, mechanisms, 151 skin antimalarial drugs, 146 lesions, classification, 146 Lupus pernio, 146 splenic, abdominal tract, 150 treatment, 161 upper respiratory tract, SURT, 150 Extrinsic allergic alveolitis (EAA) CD4:CD8 ratio, 41 cellular BALF profile, 41 hypersensitivity pneumonitis, 42 lipid-laden AMs, 42 oxygen free radicals, 40 F Farmer s lung emphysematous changes, 244 IgG response, 241 prevents (OR) control, 241 source, antigen, 240 treatment, 249 G GGO. See Ground glass opacification Goodpasture s disease alpha 3 collagen chain, 381 alveolar hemorrhage, 381 antibodies, 381 anti-gbm, 381 development factors, 381 diagnosis, outcome, 381 pulmonary and systemic symptoms, 381 treatment, 382 Goodpasture s syndrome, 331, 366, 382 Granulomas GLUS syndrome, 158 hepatic sarcoidosis, 147 histologic features, 155 inflammatory lesions, 146 non-necrotizing, sarcoid inflammation, 141 synovial biopsy, 151 TNF mediator, 142 Ground glass opacification (GGO), 197 H Hemorrhagic cystitis, 109 Hermansky Pudlak syndrome (HPS) character, 309 fibrosis, High-resolution computed tomography (HRCT) bronchial wall thickening, 92 DLD diagnosis, 94 focal consolidation, 91 ground-glass abnormality, 91 lung disease, 320 NSIP characterization, 207 radiologic characteristics, 197, serial, 200, 208 surgical lung biopsy, 200, 207 radiologic evaluation diagnosis, diffuse lung disease, differential diagnosis, infiltrative lung diseases, 18, 20 techniques, thickened interlobular septa, 20, 21 surgical lung biopsy, 97 traction bronchiectasis, 88 HP. See Hypersensitivity pneumonitis HPS. See Hermansky Pudlak syndrome HRCT. See High-resolution computed tomography Hypersensitivity pneumonitis (HP) acute chest radiograph, 242 high-resolution computed tomography, 242 laboratory test, 242 organic dust toxic syndrome (ODTS), 242 provoking agent, 241 symptoms, caveats, 65 chronic chest radiographs, 245 diagnosis, 245 diffuse coarse reticulonodular opacities, 245 high-resolution computed tomography, 245 mosaic pattern, 244 peribronchiolar inflammation, 244 symptoms, 244 description, 29 diagnostic assessment algorithm, 246, 247 clinical syndromes, 245 precipitating IgG antibody, 246 differential diagnosis, 19, 64 65
7 Index drug-induced, 44 epidemiology and risk factors etiologic agents, 240 MHC class I, class II alleles, non-tuberculous mycobacteria (NTM), 241 pigeon breeder s disease (PBD), 241 prevalence and incidence, etiologic agent, 239, 240 foamy/lipid-laden AM, 42 histologic findings, 64 increased Lym, 45 invasive tools for diagnosis bronchoalveolar lavage, histopathology, 248 inhalation challenge, 248 nodules, ground glass density, 18, 20 subacute air trapping, 243 bronchiolocentric micronodules, 243 diagnosis, 243 gradual development, histopathology, 243 lung fields, 243 pulmonary function test, 243 treatment and outcome, 249 upper lobe predominance, 25 I Idiopathic interstitial pneumonias (IIPs) AIP, 91 clinical characteristics, 197 COP, IPF, 88 LIP, 92 NSIP, provisional type, NSIP, 195 RBILD and DIP, unclassifiable, 92 Idiopathic pulmonary fibrosis (IPF) acute exacerbations, 173 acute respiratory failure, 188 biopsy diagnosis, 55 caveats, UIP, 55 clinical course and prognosis heterogeneous, 172 survival, 172 differential diagnosis, epidemiology chronic aspiration, 174 environment role, 174 infections, 174 meta-analysis, 174 occupational disease, 174 genetics, high-resolution computed tomography (HRCT), 88 histopathology, 88 incidence, 174 lung transplantation, novel agents anticoagulants, 188 interferon-g (IFN-g ), 188 pirfenidone, 188 PAH, pathogenesis, prognosis and thearpy, 172 radiographic manifestations, relative frequency, clinicopathologic sub groups, 88, 90 surgical lung biopsy(slb), 172 therapy ancillary, 187 indications, responses, 187 treatment, UIP clinical features, features, 172 pattern, 172 IIPs. See Idiopathic interstitial pneumonias ILDs. See Interstitial lung diseases Interstitial lung diseases (ILDs). See also Pulmonary hypertension connective tissue disease anti-tnf drugs, 229 assessment and management, 230 autoantibodies, azathioprine, 229 bronchoscopic evaluation, 221 clinical manifestation, 223 corticosteroids, cyclophosphamide, 228 cyclosporine, 229 drug induced lung disease, 220 lung transplantation, 230 management considerations, 227 mycophenolate mofetil, pulmonary hypertension, surgical lung biopsy, tacrolimus, 229 diagnostic approach, 38 differential diagnosis, diffuse, 42 drug therapy antimalarial agents, azathioprine, classification, common toxicities and suggested monitoring, 103 corticosteroids, 102, cyclophosphamide, leflunomide, 106 methotrexate, mycophenolate mofetil, 108 N -acetyl cysteine, 107 pirfenidone, rituximab, sirolimus, 114 thalidomide, 110 usual dosage, 103 patient evaluation ( see Patient evaluation) 393
8 394 Index Invasive tools, HP bronchoalveolar lavage alveolitis, 247 BAL neutrophils, 248 granulomatous diseases, 247 histopathology fibrosis, non-specific interstitial pneumonia pattern (NSIP), 249 patchy mononuclear cell infiltration, 248 terminal bronchioles, 248 inhalation challenge provocation test, 248 suspected agent, 248 IPF. See Idiopathic pulmonary fibrosis L LAM. See Lymphangioleiomyomatosis Langerhans cell histiocytosis (LCH), 303 LCH. See Langerhans cell histiocytosis Leflunomide, 106 LIP. See Lymphocytic interstitial pneumonia Lipoid pneumonia alveolar macrophages, 307 description, 306 oils, treatment, 307 Lung biopsy alveolar red blood cells, 63 bronchiolitis, 68 pattern recognition, 57 protocol, 278 tissue diagnosis, 50 UIP, 55 VATS, 278 Lung dominant connective tissue disease, Lung fibrosis, 249 Lung transplantation bone marrow graft airflow obstruction development, 354 chronic GVHD, 353 description, 353 disorders, 353 hematopoietic stem cell transplantation, 354 hypogammaglobulinemia, 354 photo-dynamic therapy, 354 prevalence, risk and infection, 354 obliterative bronchiolitis acute cellular rejection, 352 autoimmune injury, 353 biopsies surveillance, 353 clinical outcomes, 352 description, 351 diagnosis, BOS, function tests, 352 histopathological changes, 352 imaging, 352 lymphocytic inflltration, 352 management and rejection process, 353 re-transplantation, 353 survival, 352 transbronchial biopsies, 353 treatment, 353 paraneoplastic pemphigus, Lymphangioleiomyomatosis (LAM) biopsy diagnosis, 66 caveats, 66 differential diagnosis, epidemiology, 301 extrapulmonary features, 302 histologic findings, 65 imaging and diagnosis basilar and peripheral, 303 LCH, management angiomyolipoma, pleural disease, 304 progression, 304 pulmonary disease, pathophysiology hematoxylin and eosin, 301, 302 TSC1 and TSC2, presenting features, prognosis, 305 pulmonary physiology, 302 tuberous sclerosis (TS), 300 Lymphangitic carcinomatosis description, 311 Kerley s B line, 312 transbronchial biopsy, 312 Lymphocytic interstitial pneumonia (LIP) hypoxemia, 92 lymphoproliferative disorder, 92 Lymphocytic pneumonia, 330 M Methotrexate, , 162, 335, 375 Microscopic polyangiitis clinical presentation and diagnosis biopsy, 377 features, 377 treatment and prognosis C-ANCA and P-ANCA, 378 induces remission, 378 manifestation, 378 prognostic factor, survival, 377 M. tuberculosis, Mycophenolate mofetil (MMF) connective tissue disease, drug therapy, 108 N N -acetyl cysteine (NAC), 107 Neuroendocrine cell hyperplasia of infant (NEHI) ABCA3, BPD,
9 Index corticosteroids, 284 etiology, 284 Neurofibromatosis (NF), 310 NF. See Neurofibromatosis Nonspecific interstitial pneumonia (NSIP) autoimmune serologies, 90 biopsy diagnosis, 56 caveats, 56 clinical characteristics auto-antibody prevalence, 197, 201 description, diagnostic criteria, 197, 201 IIPs and bronchoalveolar lavage, 197 interstitial lung disease and pulmonary physiology, 197 laboratory evaluation, 197, 200 Raynaud s phenomenon, 197 UCTD, 197 description, 195 differential diagnosis, histologic findings, 55 hypersensitivity pneumonitis, 88 inflammation and fibrosis, 90 management and treatment azathioprine/cyclophosphamide, 209 survival and response, patients, nomenclature, 195 pathogenesis CTD and fibrotic lung disease, 196 DC and IPF, 196 idiopathic, 196 vs.uip, 196 pathologic characteristics agreement level, 208 description, features, 201, 209 histological features, 201, 209 surgical lung biopsies, 201, 208 prognosis histological features, 209 IPF/CFA, 209 radiographic characteristics description, 197, GGO, 197 HRCT features, 197, 207 vs. IPF, 200 serial radiographic, 200, 208 surgical lung biopsy, HRCT, 200, 207 NSIP. See Nonspecific interstitial pneumonia O Occupational and drug-induced disorders acute alveolar damage, 338 acute beryllium characteristics, 325 clinical features, 325 definition, 325 diagnosis and treatment, 325 manifestation and pathological examination, anti-inflammatory drugs aspirin, 335 leukotriene, 335 methotrexate, 335 naproxen, 335 penicillamine, 335 antineoplastic agents bleomycin, 337 busulfan, 337 cyclophosphamide, 337 dyspnea, mitomycin C, lung toxicity, 337 nitrosoureas, 337 procarbazine, 337 asbestosis, lungs and pleura accumulation, 324 clinical features, 324 description, 324 environmental and domestic exposure, 324 fiber retention, 324 lung function and clinical diagnosis, 325 lymph node, 324 plain chest radiogram, cardiovascular drugs amiodarone, 326 angiotensin-converting enzyme (ACE), 326 beta-adrenergic antagonists, 326 protamine sulfate, 326 clinical features breathlessness, cough, 322 diagnosis and complications, 323 radiographic and lung function, treatment, 323 coal workers pneumoconioses ( see Pneumoconioses) drug-induced DLDs ( see Drug-induced diffuse lung disease) drug induced lung disease, hard metal disease Cobalt exposure, 326 diagnosis, 326 leukocyte inhibition, 326 rhinitis and fibrosing alveolitis, 326 sintering process, 325 steroids and cyclophosphamide, 326 illicit cocaine, 338 heroin, 338 methadone and propoxyphene, 338 induced lung disease description, 319 environmenal issues, 320 pneumoconioses (see Pneumoconioses) respiratory effects, inhalants, 338 respiratory effects, silicosis, Organizing pneumonia +/-bronchitis pneumonia (BOOP), 329
10 396 Index P Patient evaluation clinical history acute vs. chronic onset, 4 demographic and family factor, 6 extrapulmonary symptoms, 6 occupational and environmental exposure history, 4 racial factors, 6 radiation and drug exposures, 6 respiratory symptoms, 4, 5 smoking, 5 6 invasive testing, 15 key elements, laboratory testing additional tests, 9 10 invasive procedures, peripheral blood and urine, 9 10 pulmonary function, 11 noninvasive testing, 14 physical examination extrapulmonary signs, 8 pulmonary findings, 7 8 thoracic imaging, 8 9 PBD. See Pigeon breeder s disease Pediatric, ILDs. See Childhood interstitial lung diseases Perinuclear-Antineutrophic cytoplasmic autoantibodies (P-ANCA), 366, , 382 PFT. See Pulmonary function tests PFTs. See Pulmonary function tests PIG. See Pulmonary interstitial glycogenosis Pigeon breeder s disease (PBD) data indicates, 241 indoor microbial contamination, 249 provocation test, 248 Pirfenidone, , 188 PLCH. See Pulmonary Langerhans cell histiocytosis PMN. See Polymorphonuclear neutrophils Pneumoconioses asbestosis, 69 berylliosis, 69 caveats, 69 coal worker Caplan s syndrome, 323 chest radiography, 324 clinical features, 324 develop silicotic nodules, 323 diagnosis and management, 324 lesion, 323 lung function, 324 macrophages and fibroblasts accumulation, 323 reumatoid, 323 tissue ration, 323 description, 68 histiocytic dust macules, 68 induced lung disease characteristics, 321 chest roentgenography, 320 clinical implications and risk, 320 CT and HRCT, 320 dust accumulation, lungs, 320 function and test, 320 particles deposition, 320 interstitial inflammation and peribronchiolar airspaces, 69 silicosis/silicatosis, Polymorphonuclear neutrophils (PMN) characteristic, 43 Eos and, 43 Progressive multifocal leukoencephalopathy (PML), 113 Pulmonary alveolar microlithiasis (PAM) chest radiograph, mutations, 310 ossification, 311 Pulmonary alveolar proteinosis (PAP) biopsy diagnosis, 65 causes, 287 caveats, 65 clinical presentation bronchoscopy, 298, 299 crazy-paving, dyspnea, 297 hematologic malignancies, description, 294 differential diagnosis, 65 geneticmolecular basis, 288 GM-CSF, histologic findings, 65 pathogenesis ABCA3, 297 GM-CSF, 294, 297 treatment GM-CSF, therapies, 300 WLL, 299 Pulmonary arterial hypertension (PAH) ancillary staging techniques, 183 BAL, 183 CRP scores, CT scans, 182 histological features, 179 HRCT, hypoxemia, minute walk test, MRI, 183 survival rates, 182 Pulmonary fibrosis collagen vascular disease, 44 sarcoidosis patients, 39 Pulmonary function tests (PFTs) deconstructing complex patterns ancillary tests, 78 disease processes, 77 emphysema, 77 FVC/DLco ratio, 78 Kco levels, 78 lymphocytic bronchiolitis, 78 pathological processes, 78 description, 72 diagnosis, 143
11 Index fitness to fly tests gold standard means, 82 hypoxaemia, 82 hypoxic inhalation, predictive equations, 82 plethysmograph and reduce oxygen conc., 82 ILD, 277 impairment airway component, 74 alveolar-arterial oxygen, 73 bronchiolar disorders, 74 disproportionate reduction, function, 73 hypersensitivity pneumonitis, 74 muscle weakness, 74 pulmonary vascular disease, 74 reduction in DLco, 73 restrictive ventilatory defect, 74 infant, 277 monitoring changes in disease severity, 78 clinical indication, 79 diagnosis and management, 80 DILDs, emphysema, pulmonary fibrosis, 80 forced vital capacity (FVC), 79 indications ambulatory oxygen, 81 marginal reduction, 79 precedence established, PAH, 80 short term PFT, 79 significant changes, 79 PF variables, 72 prognostic evaluation stages arterial hypoxaemia, 76 CRP, 76 DLco advantages, HRCT, 75 idiopathic pulmonary fibrosis, 75 maximal exercise test, 76 PFT use, 75 prognostic value, 76 scleroderma lung, 77 quality assurance, sarcoidosis lung restriction, 75 morphologic abnormalities, 75 non-caseating granulomas, scadding stage I radiographs, 144 use ancillary role, 72 dyspnoea, 73 lung volumes, 72 minor reductions, 72 multi-compartment disorders, 73 musculoskeletal limitation, 73 patient cohorts, 72 routine baseline stage, 2 workup, granulomatous inflammation, 144 Pulmonary hypertension CAT, IPF, 122 clinical implications, diagnosis, DOE, 121 FDA and WHO group 1, 129 forced vital capacity (FVC), 122 Group 3, PH, 123 microscopic vessels, min walk test (6MWT), 121 N -acetyl cysteine (NAC), 122 physiologic and pathological features, 123 RHC hemodynamics, 123 right heart catheterization (RHC), 122 sarcoidosis, stage IV, 122 transplantation, 132 treatment, Pulmonary interstitial glycogenosis (PIG) cells, 284, 285 etiology, Pulmonary Langerhans cell histiocytosis (PLCH) chest imaging, clinical features, 261 diagnosis, 263 history, pathology, physiology, 262 relationship, smoking, 261 treatment, Pulmonary sarcoidosis dyspnea diagnostic considerations, patients, SAPH, 145 treatment, high frequency, lung involvement, 142 imaging chest CT scanning, scadding scale, CXR classification system, 142, 143 PFTs, physiologic tests, 144 symptoms and signs, 142 Pulmonary vasculitis alveolar hemorrhage syndrome, 366 ANCA, autoantibodies, 366 Behçet s disease, C-ANCA and P-ANCA, 366 churg strauss syndrome ( see Churg strauss syndrome) classic polyarteritis nodosa, 378 connective tissue disorders, 366 constitutional symptoms, 366 description, 365 disorders characterization, 366 forms, 365 giant cell arteritis affect women, 379 bilateral biopsies, 380 Caucasians, 379 complications, 380 cough and aortic arch syndrome, 379 diagnosis, 380 epidemiology and manifestation, 379 inflammation, 379
12 398 Index Pulmonary vasculitis (cont.) seldom and prednisone therapy, 380 symptoms, 379 Goodpasture s disease ( see Goodpasture s disease) immunosuppressive therapy, 366 microscopic polyangiitis ( see Microscopic polyangiitis) pauci-immune capillaritis, 379 syndrome, Takayasu s arteritis, 380 Wegener s granulomatosis ( see Wegener s granulomatosis) Q Quality assurance biological control data, 81 cotes states, 81 inter-laboratory variability, 82 quality control and quality assurance, 81 rigorous quality assurance, 81 trend analyses, 81 two decades, 81 R Radiographic manifestations, IPF conventional chest, 175 CT, cystic radiolucencies, 176 diagnosis, UIP, 176 honeycomb change (HC), 177, 178 pulmonary function tests, 189 Radiologic evaluation characterization, interstitial lung disease biopsy, 27 first choice diagnosis, 26 usual interstitial pneumonia (UIP), collagen vascular disease, 28 CT techniques attention, requirement, HRCT images, 17, 18 cystic lung diseases LAM, 30 PLCH, 30 detection, early interstitial lung disease, 26 diagnosis, diffuse lung disease HRCT, 31 strategy, CT features, 31, 32 diffuse lung disease, signs consolidation, 18 crazy paving pattern, cysts, 22 ground-glass attenuation, 18 honeycombing, 22 lines, mosaic attenuation, 23, 24 mosaic pattern, nodules, traction bronchiectasis/bronchiolectasis, 22 distribution, lung diseases differential diagnosis, 24, 25 interlobular septa, perilymphatic abnormalities, 24 secondary pulmonary lobule, tree-in-bud sign, 21, 25 upper and lower, predominant, 24, 25 hypersensitivity pneumonitis, 29 idiopathic interstitial pneumonias consolidation, 28 diagnosis, UIP, fibrosis, 27 multidisciplinary workshop, 28 predominant CT pattern, 27 sarcoidosis fibrotic, 27, 29 lymphadenopathy and nodules, small airways disease cellular bronchiolitis, 30 constrictive bronchiolitis, 30 CT-based classification, 30, 31 panbronchiolitis, 31 smoking-related lung diseases description, 29 DIP, RB-ILD, 29 Rare interstitial lung diseases (ILDs) amyloidosis, aspiration, BAC, 311 Erdheim Chester disease, 309 HPS, information, LAM, lipoid pneumonia, lymphangitic carcinomatosis, NF, 310 PAM, PAP, 294, PLCH, 305 Raynaud s phenomenon, 197 RB-ILD. See Respiratory bronchiolitis-associated interstitial lung disease Respiratory bronchiolitis-associated interstitial lung disease (RB-ILD) focal air trapping, 92 pulmonary function, 91 respiratory bronchiolitis, 92 Respiratory bronchiolitis interstitial lung disease chest imaging, 256 clinical features, 256 history, pathology and diagnosis, 257 physiology, relationship, smoking, 256 treatment, Rheumatologic diseases, 218, 219 Rituximab,
13 Index S SAPH. See Sarcoidosis-associated pulmonary hypertension Sarcoidosis biopsy diagnosis, biopsy site selection CD4/CD8 ratio, 155 clinical presentations, 154 morbidity and risk complications, 154 TBLB, caveats, 54 CD4:CD8 ratio, 41 clinical findings clinicoradiographic data, 154 SACE, 153 clinical vignette, decision, treat, definition/diagnosis, 140 description, 140 diagnosis algorithm, 154 differential diagnosis, 53 different lobes, 40 EAA, 42 exclusion, granulomatous inflammation, 155 extrapulmonary, fibrotic, 27, 29 histologic findings, 53 idiopathic systemic, granulomatous disease, 158 immunopathogenesis and pathology epidemiologic evidence, 140 genetic predisposition, 141 inflammation, non-necrotizing granulomas, 141 mediator, TNF, 142 Th1-predominant cytokine profile, inflammation and organ systems, 42 Kveim test, 158 lymphadenopathy and nodules, lymphocyte alveolitis, 42 multiple organ involvement ACCESS, 156 idiopathic panuveitis, 156 organ involvement, patients, pathologic diagnosis, 156 pathology, 155 penumbra, 160 prognosis acute and chronic, 164 factors, extrapulmonary, 165 mortality, 165 therapy, natural history, time frame, resolution, 164 pulmonary, Sarcoidosis-associated pulmonary hypertension (SAPH), 145 Scleroderma (SSc), 124 Silicosis accelerated, 322 acute, 322 chronic, 320, 321 collagen deposition, 322 development, 322 dust exposure, occupation, extra-thoracic manifestation, 322 features, 322 meaning, 320 Sirolimus, 114 Smoking-related interstitial lung disease AEP (see Acute eosinophilic pneumonia) anti-gbm disease, 265 combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis, 264 desquamative interstitial pneumonia, pulmonary Langerhans cell histiocytosis, respiratory bronchiolitis interstitial lung disease, Staging disease severity arterial hypoxaemia, 11 high resolution computed tomography (HRCT), 11 idiopathic pulmonary fibrosis, 11 uses, 11 Steroid-sparing medications azathioprine, methotrexate, 162 Subacute cellular interstitial pneumonitis, Surfactant protein B ABCA3 mutations, 282 chest radiographs, 281 mutation, 279 Surfactant protein C (SFTPC) cystic lesions, 285, 286 pathogenesis, 286 presentation, 285 RSV, 286 Surgical lung biopsy (SLB) accurate histopathologic evaluation, 94 bronchiolitis, 68 clinical setting, 62 connective tissue disease, interstitial lymphocytic infiltrate, 92 patient evaluation, 12 pattern recognition, 57 respiratory bronchiolitis pattern, 92 role clinical diagnosis accuracy, IPF, clinicopathologic subclassification, 95 response, treatment, 95 survival, UIP, 55 usual interstitial pneumonia (UIP), 88 T Tacrolimus, 229 TBBx. See Transbronchial biopsies Thalidomide, 110 Thiopurine S-methyltransferase (TPMT), 107 TNF antagonists, 164 Transbronchial biopsies (TBBx) alveolar hemorrhage, 63 histologic changes, 50 sarcoidosis, 52 tissue sampling, 50 Transbronchial biopsy, 12
14 400 Index U UCTD. See Undifferentiated connective tissue disease UIP. See Usual interstitial pneumonitis Undifferentiated connective tissue disease (UCTD), 197, 225 Usual interstitial pneumonitis (UIP) cardinal histopathological findings, 172 clinical features elevations, BALF, 173 physical examination, CT diagnosis, differential diagnosis, infiltrative lung diseases, 25 pathogenesis alveolar epithelial cell (EC) injury, 183 dysregulation of fibroblasts (FBs), 183 fibroblastic foci (FF), 184 inflammation and fibrosis, 184 mechanisms, 184 myofibroblast differentiation and fate, 184 reticular lines, 21 V Vasculitis biopsy diagnosis, 62 caveats, 62 Churg Strauss syndrome, 60 differential diagnosis, histologic findings, microscopic polyangiitis, 60 Wegener s granulomatosis, 60 VATS. See Video-assisted thoracoscopic surgery Video-assisted thoracoscopic surgery (VATS), 12, 272 W Wegener s granulomatosis beyond standard therapy B-cell-targeted therapy, 376 explanattion, 376 infliximab, 376 investigation, T-cell function, 376 outcomes, 376 plasma exchange, 376 therapeutic agents, 376 biopsy diagnosis, 372 renal and open lung, 373 side effects, 372 blood counts and serology, 370 bronchoscopy, 372 clinical management algorithm treatment, 374 fatal disease, 374 immunosuppressive therapy, 374 induction therapy, 374 manifestations, 374 clinical presentation abnormalities, 368 affect skin, 369 alveolar hemorrhage, 368, 370 C-ANCA, control, 369 description, 368 diagnosis, granulomatous involvement, 369 inflammation and nasal cartilage, 368 manifestation, 369 necrotizing, 368 ophthalmologic involvement, 369 pathognomonic feature, 368 renal outcome, 369 severe headache, 369 symptoms and manifestations, 368 investigations, 370 limited disease, induction therapy, 375 maintenance remission azothioprine, 375 methotrexate, 375 mycophenolate mofetil, 375 therapy duration, 376 trimethoprim/sulfamethoxazole, monitoring therapy, pulmonary function test determination, 372 diffusing capacity, 372 dyspnea, 372 flow volume loop, 372, 373 function data, 372 visual inspection, 372 radiography alveolar hemorrhage, diffuse infltrates, 371 chest roentgenogram and CT, 370 CT and MRI scan, effusions, 371 lesions, 371 lesions cavitate, nodules/masses, 369 pathognomonic feature, 368, 371 remission induction cyclophosphamide, 374, 375 efficacy, 375 infection rate, 375 limit toxicity, 375 management problems, 374 rituximab, 375 standard regimen, 374 treatment, 374 sequelae management, 376 Whole lung lavage (WLL), 299 WLL. See Whole lung lavage
Manish Powari Regional Training Day 10/12/2014
Manish Powari Regional Training Day 10/12/2014 Large number of different types of Interstitial Lung Disease (ILD). Most are very rare Most patients present with one of a smaller number of commoner diseases
More informationOutline Definition of Terms: Lexicon. Traction Bronchiectasis
HRCT OF IDIOPATHIC INTERSTITIAL PNEUMONIAS Disclosures Genentech, Inc. Speakers Bureau Tadashi Allen, MD University of Minnesota Assistant Professor Diagnostic Radiology 10/29/2016 Outline Definition of
More informationCase Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco
Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary
More information4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs
Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation
More informationFinancial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature
Financial disclosure I have no financial relationships to disclose. Douglas Johnson D.O. Cardiothoracic Imaging Gaston Radiology COMMON DIAGNOSES IN HRCT High Res Chest Anatomy Nomenclature HRCT Sampling
More informationA Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco
A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Why it is important Definition/Classification
More informationA Review of Interstitial Lung Diseases
Outline A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Overview of diagnosis in ILD Why it is important Definition/Classification
More informationEpidemiology and classification of smoking related interstitial lung diseases
Epidemiology and classification of smoking related interstitial lung diseases Šterclová M. Department of Respiratory Diseases, Thomayer Hospital, Prague, Czech Republic Supported by an IGA Grant No G 1207
More informationCase 1 : Question. 1.1 What is the intralobular distribution? 1. Centrilobular 2. Perilymphatic 3. Random
Interesting case Case 1 Case 1 : Question 1.1 What is the intralobular distribution? 1. Centrilobular 2. Perilymphatic 3. Random Case 1: Answer 1.1 What is the intralobular distribution? 1. Centrilobular
More informationINTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018
INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial
More information11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective Radiology Pathology Clinical 1 Role of HRCT Diagnosis Fibrosis vs. inflammation Next step in management Response to treatment
More informationCase 1: Question. 1.1 What is the main pattern of this HRCT? 1. Intralobular line 2. Groundglass opacity 3. Perilymphatic nodule
HRCT WORK SHOP Case 1 Case 1: Question 1.1 What is the main pattern of this HRCT? 1. Intralobular line 2. Groundglass opacity 3. Perilymphatic nodule Case 1: Question 1.2 What is the diagnosis? 1. Hypersensitivity
More information5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective No, I am not a pulmonologist! Radiology Pathology Clinical 1 Everyone needs a CT Confidence in diagnosis Definitive HRCT +
More informationDifferential diagnosis
Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential
More informationDisclosures. Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting. Relevant financial relationships: None. Off-label usage: None
Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona
More informationCTD-related Lung Disease
13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of
More informationAcute and Chronic Lung Disease
KATHOLIEKE UNIVERSITEIT LEUVEN Faculty of Medicine Acute and Chronic Lung Disease W De Wever, JA Verschakelen Department of Radiology, University Hospitals Leuven, Belgium Clinical utility of HRCT To detect
More informationHYPERSENSITIVITY PNEUMONITIS
HYPERSENSITIVITY PNEUMONITIS A preventable fibrosis MOSAVIR ANSARIE MB., FCCP INTERSTITIAL LUNG DISEASES A heterogeneous group of non infectious, non malignant diffuse parenchymal disorders of the lower
More informationCLEARING THE AIR ON DIFFUSE PARENCHYMAL (INTERSTITIAL) LUNG DISEASE (ILD)
CLEARING THE AIR ON DIFFUSE PARENCHYMAL (INTERSTITIAL) LUNG DISEASE (ILD) David Northrop MBA, RRT Assistant Director of Respiratory Therapy Services The University of Kansas Health System Clinical Assistant
More informationHRCT in Diffuse Interstitial Lung Disease Steps in High Resolution CT Diagnosis. Where are the lymphatics? Anatomic distribution
Steps in High Resolution CT Diagnosis Pattern of abnormality Distribution of disease Associated findings Clinical history Tomás Franquet MD What is the diagnosis? Hospital de Sant Pau. Barcelona Secondary
More informationI have no relevant conflicts of interest to disclose
I have no relevant conflicts of interest to disclose Diffuse parenchymal lung disease (DPLD) and its associations Secondary lobular anatomy DPLD History, clinical findings, temporal evolution, and exposures
More informationLiebow and Carrington's original classification of IIP
Liebow and Carrington's original classification of IIP-- 1969 Eric J. Stern MD University of Washington UIP Usual interstitial pneumonia DIP Desquamative interstitial pneumonia BIP Bronchiolitis obliterans
More informationImaging Small Airways Diseases: Not Just Air trapping. Eric J. Stern MD University of Washington
Imaging Small Airways Diseases: Not Just Air trapping Eric J. Stern MD University of Washington What we are discussing SAD classification SAD imaging with MDCT emphasis What is a small airway? Airway with
More informationINTERSTITIAL LUNG DISEASE Dr. Zulqarnain Ashraf
Indep Rev Jul-Dec 2018;20(7-12) Dr. Zulqarnain Ashraf IR-653 Abstract: ILD is a group of diseases affect interstitium of the lung. Repeated insult to the lung cause the interstitium to be damaged. Similarly
More informationNon-neoplastic Lung Disease II
Pathobasic Non-neoplastic Lung Disease II Spasenija Savic Prince Pathology Program Systematic approach to surgical lung biopsies with ILD Examples (chronic ILD): Idiopathic interstitial pneumonias: UIP,
More informationDiagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines
Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines Rebecca Keith, MD Assistant Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO Objectives
More informationThe Pathologic Manifestations of Small Airway Disease. Samuel A. Yousem, MD. Small Airway Disease (SAD) SAD
The Pathologic Manifestations of Small Airway Disease Samuel A. Yousem, MD Small Airway Disease (SAD) A clinicopathologic syndrome reflecting a CHRONIC inflammatory and cicatricial process primarily affecting
More informationReplacement of air with fluid, inflammatory. cells or cellular debris. Parenchymal, Interstitial (Restrictive) and Vascular Diseases.
Parenchymal, Interstitial (Restrictive) and Vascular Diseases Alain C. Borczuk, M.D. Dept of Pathology Replacement of air with fluid, inflammatory cells Pulmonary Edema Pneumonia Hemorrhage Diffuse alveolar
More informationKaterina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School, University of Crete Prague, June 2014
Hypersensitivity pneumonitis: Causes, clinical course, diagnosis and differential diagnosis, treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationDéjà vu all over again
Disclosures Déjà vu all over again None Jonathan Singer MD MS University of California, San Francisco HPI 49 y/o woman presents for lung transplant evaluation for Hypersensitivity Pneumonitis Exposures:
More informationBronkhorst colloquium Interstitiële longziekten. Katrien Grünberg, klinisch patholoog
Bronkhorst colloquium 2013-2014 Interstitiële longziekten De pathologie achter de CT Katrien Grünberg, klinisch patholoog K.grunberg@vumc.nl Preparing: introduction and 3 cases The introduction on microscopic
More informationDefinition, classification and epidemiology
Interstitial Lung Diseases Definition, classification and epidemiology Haluk Türktaş Professor of Pulmonary Medicine Gazi University Ankara Interstitial Lung Diseases Definition of ILD A diverse group
More informationInterstitial Lung Diseases(ILD) By : Dr. Shaher M. Samrah Done by : Ibrahim M. sun
Interstitial Lung Diseases(ILD) By : Dr. Shaher M. Samrah Done by : Ibrahim M. sun. 26.11.11 Introduction Interstitial Lung Diseases (ILD) are group of diseases that affect the interstitium of the lungs,
More informationInternational consensus statement on idiopathic pulmonary fibrosis
Eur Respir J 2001; 17: 163 167 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 PERSPECTIVE International consensus statement on idiopathic
More informationRadiologic Approach to Smoking Related Interstitial Lung Disease
Radiologic Approach to Smoking Related Interstitial Lung Disease Poster No.: C-1854 Congress: ECR 2013 Type: Educational Exhibit Authors: K.-N. Lee, J.-Y. Han, E.-J. Kang, J. Kang; Busan/KR Keywords: Toxicity,
More informationDiffuse Interstitial Lung Diseases: Is There Really Anything New?
: Is There Really Anything New? Sujal R. Desai, MBBS, MD ESTI SPEAKER SUNDAY Society of Thoracic Radiology San Antonio, Texas March 2014 Diffuse Interstitial Lung Disease The State of Play DILDs Is There
More informationLines and crackles. Making sense of ILD
Lines and crackles Making sense of ILD Case JM 65 year old male Gradual shortness of breath, going on over a year Some dry cough Ex-smoker, quit 10 years ago Crackles in the bases CXR presented Sent to
More informationBronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy
Idiopathic Pulmonary Fibrosis Bronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy JMAJ 46(11): 469 474, 2003 Yukihiko SUGIYAMA Professor, Division of Pulmonary Medicine, Department of
More informationDaria Manos RSNA 2016 RC 401. https://medicine.dal.ca/departments/depar tment-sites/radiology/contact/faculty/dariamanos.html
Daria Manos RSNA 2016 RC 401 https://medicine.dal.ca/departments/depar tment-sites/radiology/contact/faculty/dariamanos.html STEP1: Is this fibrotic lung disease? STEP 2: Is this a UIP pattern? If yes:
More informationPathologic Assessment of Interstitial Lung Disease
Pathologic Assessment of Interstitial Lung Disease Dry and itchy? It could be eczema or fungal infection. We don t need to worry, the drugs aren t that dangerous. Kirk D. Jones, MD UCSF Dept. of Pathology
More informationChest imaging II. Interstitial lung diseases
Chest imaging II. Interstitial lung diseases Dávid L. Tárnoki MD, PhD Ádám D. TárnokiMD, PhD Department of Radiology Semmelweis University Topics 1. Interstitial lung diseases 2. Occupational lung diseases
More informationHypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas
Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas Rishi Raj MD Director, Interstitial Lung Diseases Program Clinical Professor of Pulmonary and Critical Care Medicine Stanford University
More informationDiagnostic challenges in IPF
Medicine, Nursing and Health Sciences Diagnostic challenges in IPF Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University March 2015 Disclosures Consultancy fees from
More informationUsual Interstitial pneumonia and Nonspecific Interstitial Pneumonia. Nitra and the Gangs.
Usual Interstitial pneumonia and Nonspecific Interstitial Pneumonia Nitra and the Gangs. บทน ำและบทท ๓, ๑๐, ๑๒, ๑๓, ๑๔, ๑๕, ๑๗ Usual Interstitial Pneumonia (UIP) Most common & basic pathologic pattern
More informationSCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW
SCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW Lung disease can be a serious complication of scleroderma. The two most common types of lung disease in patients with scleroderma are interstitial
More informationAtlas of the Vasculitic Syndromes
CHAPTER e40 Atlas of the Vasculitic Syndromes Carol A. Langford Anthony S. Fauci Diagnosis of the vasculitic syndromes is usually based upon characteristic histologic or arteriographic findings in a patient
More informationIPF: Epidemiologia e stato dell arte
IPF: Epidemiologia e stato dell arte Clinical Classification Diffuse parenchimal lung diseases Exposure-related: - occupational - environmental - medication Desquamative interstitial pneumonia Idiopathic
More informationRadiological Imaging of Drug-Induced Pulmonary Lesions
Review Article imedpub Journals www.imedpub.com Journal of Clinical Radiology and Case Reports Radiological Imaging of Drug-Induced Pulmonary Lesions D souza M *, Rajiah P, Khan A and Irion K Department
More informationINDEX. surgpath.theclinics.com. Note: Page numbers of article titles are in boldface type. diffuse pleural fibrosis, pleural plaques,
INDEX Note: Page numbers of article titles are in boldface type. A Adenocarcinoma, minimally invasive. See Minimally invasive adenocarcinoma (MIA). Airway-centered interstitial fibrosis, 183 184 ALK (anaplastic
More information* * APPROACH TO NON- NEOPLASTIC LUNG DISEASE IN TRANSBRONCHIAL AND SURGICAL BIOPSIES. Financial Disclosures: NONE. BIOPSY TECHNIQUES Bronchoscopic
APPROACH TO NON- NEOPLASTIC LUNG DISEASE IN TRANSBRONCHIAL AND SURGICAL BIOPSIES Thomas V. Colby, M.D. Mayo Clinic Arizona Geraldine C. Zeiler Professor of Cytopathology Mayo Clinic Arizona Financial Disclosures:
More informationMimics in chest disease: interstitial opacities
Insights Imaging (2013) 4:9 27 DOI 10.1007/s13244-012-0207-7 PICTORIAL REVIEW Mimics in chest disease: interstitial opacities Anastasia Oikonomou & Panos Prassopoulos Received: 19 June 2012 / Revised:
More informationVascular Lung Diseases
Vascular Lung Diseases SESSION SPECIFIC OBJECTIVES List the major types of vascular lung disease Recognize and describe the pathology of vascular lung disease: Pulmonary embolism, thrombosis, hypertension,
More informationThe ABC s of ILD LIP AIP NSIP
The ABC s of ILD LIP NSIP AIP Classification Clinical Idiopathic Disorders Pulmonary Fibrosis NSIP COP AIP Sarcoidosis Connective Tissue Disease Drug-Induced Occupational/Environmental Pulmonary Alveolar
More informationChronic Interstitial (Restrictive) Lung Disease
Chronic Interstitial (Restrictive) Lung Disease Fibrosing Usual interstitial pneumonia (idiopathic pulmonary fibrosis) IPF/UIP Nonspecific interstitial pneumonia(nsip) Cryptogenic organizing pneumonia(cop)
More informationBronchiolar disorders: Current perspective on diagnosis & management. Puneet Malhotra Senior Resident, Dept. of Pulmonary Medicine, PGIMER
Bronchiolar disorders: Current perspective on diagnosis & management Puneet Malhotra Senior Resident, Dept. of Pulmonary Medicine, PGIMER Anatomic considerations Classification Diagnostic approach Specific
More informationParenchymal, Interstitial i (Restrictive) i and Vascular Diseases
Pulmonary Diseases: Structure-Function Correlation II Parenchymal, Interstitial i (Restrictive) i and Vascular Diseases Alain C. Borczuk, M.D. Dept of Pathology Pulmonary Diseases: Structure-Function Correlation
More informationPulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment
Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
More informationRestrictive lung diseases
Restrictive lung diseases Restrictive lung diseases are diseases that affect the interstitium of the lung. Interstitium of the lung is the very thin walls surrounding the alveoli, it s formed of epithelium
More informationImmune-mediated lung disease. Ian Sabroe
Immune-mediated lung disease Ian Sabroe It s all immune? Diseases that doesn t have immune involvement? The processes of response to injury and tissue repair are key homeostatic pathways involved in all
More informationDisclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:
Disclosures Pharmacological Therapy for ILD What to Use and How to Use It Harold R Collard MD Interstitial Lung Disease Program University of California San Francisco (UCSF) I have relationships with the
More informationLung Allograft Dysfunction
Lung Allograft Dysfunction Carlos S. Restrepo M.D. Ameya Baxi M.D. Department of Radiology University of Texas Health San Antonio Disclaimer: We do not have any conflict of interest or financial gain to
More informationOverview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy
Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health Disclosures Speaker - Boehringer Ingelheim and Genentech Objectives Describe
More informationTBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than
TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than PAP) BAL is not required as a diagnostic tool in patients
More informationSystemic lupus erythematosus (SLE): Pleuropulmonary Manifestations
08/30/10 09/26/10 Systemic lupus erythematosus (SLE): Pleuropulmonary Manifestations Camila Downey S. Universidad de Chile, School of Medicine, Year VII Harvard University, School of Medicine Sept 17,
More informationNONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP
UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF () FOR PATHOLOGISTS Thomas V. Colby, M.D. Professor of Pathology (Emeritus) Mayo Clinic Arizona FINANCIAL DISCLOSURES NONE OVERVIEW IPF Radiologic Dx Pathologic
More informationProgress in Idiopathic Pulmonary Fibrosis
Progress in Idiopathic Pulmonary Fibrosis David A. Lynch, MB Disclosures Progress in Idiopathic Pulmonary Fibrosis David A Lynch, MB Consultant: t Research support: Perceptive Imaging Boehringer Ingelheim
More informationThe Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page
The Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page 1135-1140 Role of High Resolution Computed Tomography in Diagnosis of Interstitial Lung Diseases in Patients with Collagen Diseases
More informationInterstitial Lung Disease
Interstitial Lung Disease Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 130 disorders which are characterized by scarring (i.e. fibrosis ) and/or inflammation
More informationWorkshop Cyst & Lucency. How to Approach
Workshop Cyst & Lucency How to Approach To Approach Cystic Lung Disease True cysts? Cavitary disease Cystic bronchiectasis Mosaic attenuation Subpleural cysts Bullae Paraseptal emphysema Honeycombing Birt
More informationUpdate on Therapies for Idiopathic Pulmonary Fibrosis. Outline
Update on Therapies for Idiopathic Pulmonary Fibrosis Paul Wolters Associate Professor University of California, San Francisco Outline Classification of Interstitial lung disease Clinical classification
More informationInterstitial Lung Disease in Infants and Children
Interstitial Lung Disease in Infants and Children David A. Mong, MD SUNDAY Andrew Mong MD Beyond the interstitium (path includes airways/airspace) Radiographic diffuse disease Adult Interstitial Lung Disease
More informationAtopic Pulmonary Disease: Findings on Thoracic Imaging
July 2003 Atopic Pulmonary Disease: Findings on Thoracic Imaging Rebecca G. Breslow Harvard Medical School Year IV Churg-Strauss Syndrome Hypersensitivity Pneumonitis Asthma Atopic Pulmonary Disease Allergic
More informationThoracic lung involvement in rheumatoid arthritis: Findings on HRCT
Thoracic lung involvement in rheumatoid arthritis: Findings on HRCT Poster No.: C-2488 Congress: ECR 2015 Type: Educational Exhibit Authors: R. E. Correa Soto, M. J. Martín Sánchez, J. M. Fernandez 1 1
More informationCystic Lung Disease. Cristopher A. Meyer, MD
Cystic Lung Disease Cristopher A. Meyer, MD Air filled structure with definable wall typically less than 1 mm thick Cris A. Meyer, M.D. Professor of Radiology University of Wisconsin School of Medicine
More informationRadiologic findings of drug-induced lung disease
Radiologic findings of drug-induced lung disease Poster No.: P-0115 Congress: ESTI 2015 Type: Educational Poster Authors: A. I. C. Santos, A. F. Roque, R. Mamede, L. Oliveira, T. Saldanha; Lisbon/PT Keywords:
More informationCASE OF THE MONTH. Lung Disease in Rheumatoid Arthritis
CASE OF THE MONTH Lung Disease in Rheumatoid Arthritis 61 year old male Maōri Height: 174 cm Weight: 104.6kg BMI: 34.55 Problems 1. Rheumatoid related interstitial lung disease with UIP pattern 2. Secondary
More informationInterstitial Lung Disease
Interstitial Lung Disease Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 130 disorders which are characterized by scarring (i.e. fibrosis ) and/or inflammation
More informationIPF - Inquadramento clinico
IPF - Inquadramento clinico Sergio Harari Unità Operativa di Pneumologia UTIR Servizio di Fisiopat. Resp. e Emodinamica Polmonare Ospedale S. Giuseppe, Milano Clinical Classification Diffuse parenchimal
More informationC h a p t e r 1 3 Interstitial Lung Disease
C h a p t e r 1 3 Interstitial Lung Disease Shirish P Shah 1, Somesh Chaudhary 2, P Shetty 2 1 Consultant Chest Physician, Nanavati Hospital, Mumbai, Former Head of Department of Chest Medicine, BYL Nair
More informationRespiratory Pathology. Kristine Krafts, M.D.
Respiratory Pathology Kristine Krafts, M.D. Normal lung: alveolar spaces Respiratory Pathology Outline Acute respiratory distress syndrome Obstructive lung diseases Restrictive lung diseases Vascular
More informationThe crazy-paving pattern: A radiological-pathological correlated and illustrated overview
The crazy-paving pattern: A radiological-pathological correlated and illustrated overview Poster No.: C-0827 Congress: ECR 2010 Type: Educational Exhibit Topic: Chest Authors: W. F. M. De Wever, J. Coolen,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Idiopathic Pulmonary Fibrosis Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Idiopathic Pulmonary Fibrosis (Esbriet /pirfenidone, Ofev /nintedanib)
More informationHistopathologic Approach to Interstitial Lung Disease
Histopathologic Approach to Interstitial Lung Disease Kirk D. Jones, MD UCSF Dept of Pathology kirk.jones@ucsf.edu Disclosures I have nothing to disclose 1 Why? Much of interstitial lung disease biopsies
More informationRadiologists toolbox to differentiate alveolar versus interstitial lung diseases
Radiologists toolbox to differentiate alveolar versus interstitial lung diseases Dr Sumer Shikhare, Dr Trishna Shimpi, Dr Ashish Chawla Khoo Teck Puat Hospital Singapore. Relevant financial disclosures
More informationResident Case Review CHEST. Daria Manos CAR 2016
Resident Case Review CHEST CAR 2016 Daria Manos Disclosure Speakers bureau, Roche CAR 2016 Daria Manos 1. Recognize common and critical chest radiograph and computed tomography signs and use these clues
More information9/15/11. Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September Scleroderma. Hard skin
Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September 2011 Scleroderma Hard skin 1 No diagnostic test for scleroderma Pathogenesis is unknown prominent features of disease reflect
More informationFollicular bronchiolitis in surgical lung biopsies: Clinical implications in 12 patients
Respiratory Medicine (2008) 102, 307 312 Follicular bronchiolitis in surgical lung biopsies: Clinical implications in 12 patients Michelle R. Aerni a, Robert Vassallo a,, Jeffrey L. Myers b, Rebecca M.
More informationIdiopathic Pulmonary Fibrosis Treatable and Not Idiopathic
Idiopathic Pulmonary Fibrosis Treatable and Not Idiopathic Brett Ley, MD University of California San Francisco CTS 1/26/18 Disclosures Speaker s bureau honorarium from Genentech (makers of pirfenidone)
More informationSpectrum of Cystic Lung Disease and its Mimics. Kathleen Jacobs MD and Elizabeth Weihe MD UC San Diego Medical Center, Department of Radiology
Spectrum of Cystic Lung Disease and its Mimics Kathleen Jacobs MD and Elizabeth Weihe MD UC San Diego Medical Center, Department of Radiology No Financial Disclosures Learning Objectives 1. Review the
More informationInterstitial Lung Disease in Children
Interstitial Lung Disease in Children Sankaran Krishnan, MD, MPH, FAAP Associate Professor, Pediatrics and Public Health Associate Program Director, Pediatric Pulmonology New York Medical College Maria
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies A Rheumatologist s Approach to Interstitial Lung Disease Outline ILD classification and patterns in CTD The clinical landscape and
More informationCase 4 History. 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar
Case 4 History 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar basilar infiltrates suggestive of pulmonary fibrosis Open
More informationChallenges in the Diagnosis of Interstitial Lung Disease
Challenges in the Diagnosis of Interstitial Lung Disease Kirk D. Jones, MD UCSF Dept. of Pathology kirk.jones@ucsf.edu Overview New Classification of IIP Prior classification Modifications for new classification
More informationI don t need you. Disclosure Statement. Pathology Approach to ILD 11/5/2016. Kirk D. Jones, MD UCSF Dept of Pathology
Pathology Approach to ILD Disclosure Statement Relevant financial relationships with a commercial interest: Boeringer Ingleheim, speaker Kirk D. Jones, MD UCSF Dept of Pathology kirk.jones@ucsf.edu I don
More informationDiagnosing ILD. What is important in 2016? Chris Grainge
Diagnosing ILD What is important in 2016? Chris Grainge Senior Staff Specialist Respiratory Medicine John Hunter Hospital Conjoint A/Prof University of Newcastle Conflict of interest I have acted as a
More informationChallenges in the Diagnosis of Interstitial Lung Disease
Challenges in the Diagnosis of Interstitial Lung Disease Kirk D. Jones, MD UCSF Dept. of Pathology kirk.jones@ucsf.edu Overview New Classification of IIP Prior classification Modifications for new classification
More informationThe connective tissue disorders (CTDs), also. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement
Eur Respir J 2009; 33: 882 896 DOI: 10.1183/09031936.00152607 CopyrightßERS Journals Ltd 2009 REVIEW Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement
More informationNoninfectious Inflammatory Lung Disease: Imaging Considerations and Clues to Differential Diagnosis
Cardiopulmonary Imaging Review Nemec et al. Noninfectious Inflammatory Lung Disease Cardiopulmonary Imaging Review Stefan Franz Nemec 1 Ronald L. Eisenberg Alexander A. Bankier Nemec SF, Eisenberg RL,
More information